Pliant Therapeutics Provides Update on BEACON-IPF
MWN-AI** Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced the discontinuation of its bexotegrast development program for idiopathic pulmonary fibrosis (IPF) following a review of data from the BEACON-IPF Phase 2b/3 clinical trial. This decision comes after a recommendation from the trial's independent Data Safety Monitoring Board (DSMB) due to an imbalance in IPF-related adverse events evident in trial participants. Full analysis indicated that at the tested doses of 160 mg and 320 mg, bexotegrast had an unfavorable risk-benefit profile, as patients exhibited an increased risk for adverse events related to disease progression, including respiratory complications and hospitalizations.
Despite minor improvements in forced vital capacity (FVC) at certain time points, the safety concerns outweighed these benefits. The company plans to submit the detailed trial results for future publication. Bernard Coulie, CEO of Pliant, expressed disappointment over the decision but emphasized the commitment to patient safety.
While the focus on IPF treatment has ended, Pliant continues with its oncology programs, particularly the Phase 1 trial for PLN-101095, a dual selective integrin inhibitor aimed at treating solid tumors. The trial has shown promising outcomes, reporting a 50% rate of confirmed partial responses at the highest dosage so far. Enrollment for further dose cohorts is ongoing.
In addition to its oncology initiatives, Pliant supports early-stage development through a proprietary platform designed for integrin-based therapeutics and their targeted delivery. The company aims to align its operational strategy to advance its pipeline, which includes a monoclonal antibody for muscular dystrophies and further exploration of tissue-specific drug delivery mechanisms.
MWN-AI** Analysis
Pliant Therapeutics, Inc. has recently announced the discontinuation of its BEACON-IPF clinical trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), following a safety review that highlighted an unfavorable risk-benefit profile. The trial's findings revealed that patients treated with bexotegrast experienced more adverse events associated with disease progression compared to those receiving placebo. This development is a significant setback for the company, and it raises questions regarding its near-term prospects.
Despite this setback in its IPF program, Pliant's ongoing clinical activities in oncology, particularly the Phase 1 trial of PLN-101095, present a more encouraging pathway. Initial results have shown promising tolerability and confirmed partial responses in patients resistant to immune checkpoint inhibitors, which could open avenues for Pliant in the competitive cancer therapy market. This emphasis on oncology and the company’s proprietary drug discovery platform, with its extensive library of integrin-binding molecules, provides a potentially broad therapeutic reach in treating various diseases.
Investors should remain cautious, given the volatility typically associated with clinical-stage biopharmaceutical companies, especially following a disappointing trial outcome. The decision to align workforce and operations suggests potential cost-cutting measures, indicating that the company may experience short-term financial pressure.
In light of these developments, current and prospective investors should closely monitor Pliant's progress in the oncology sphere while keeping an eye on its financial health. Strategies to mitigate risks could include diversifying investments across other therapeutic areas and remaining attentive to new data releases from Pliant's ongoing trials. Overall, while the discontinuation of bexotegrast is disheartening, potential opportunities in oncology may define Pliant's trajectory moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Bexotegrast development in IPF discontinued
Clinical oncology program and early-stage programs continue
Recent workforce and operational changes align with next steps
SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).
BEACON-IPF Trial Update
BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events.
Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial.
At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo.
The full results from BEACON-IPF will be submitted for future publication.
"Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.”
Oncology Phase 1 Enrollment Continues
PLN-101095 is an oral, small molecule, dual selective inhibitor of ?v?8 and ?v?1 integrins, designed to block TGF-? activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts.
Early Programs Supported by Proprietary Platform
The Company’s drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of ? v ß 8 and ? v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin ? 7 ? 1 targeting muscular dystrophies. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules.
For additional information, please visit: www.PliantRx.com . Follow us on social media X , LinkedIn and Facebook .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company’s proprietary platform; and the Company’s efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at www.sec.gov . Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ**
What were the specific reasons cited by Pliant Therapeutics Inc. (PLRX) for the unfavorable risk-benefit profile observed in the BEACON-IPF trial, leading to the discontinuation of bexotegrast in idiopathic pulmonary fibrosis (IPF)?
How does Pliant Therapeutics Inc. (PLRX) plan to pivot its focus from bexotegrast in IPF to the ongoing oncology programs, particularly in light of the Phase 1 results for PLN-101095?
In the context of recent workforce and operational changes at Pliant Therapeutics Inc. (PLRX), what strategic adjustments are being made to align resources for advancing the early-stage programs and the proprietary drug discovery platform?
With the discontinuation of bexotegrast in IPF, what are the anticipated next steps for Pliant Therapeutics Inc. (PLRX) regarding the publication and dissemination of the BEACON-IPF trial results within the scientific community?
**MWN-AI FAQ is based on asking OpenAI questions about Pliant Therapeutics Inc. (NASDAQ: PLRX).
NASDAQ: PLRX
PLRX Trading
-1.82% G/L:
$1.345 Last:
366,040 Volume:
$1.41 Open:
